The aim of this project is to expand the capabilities of a novel `liquid array'platform, based on Encoded Sortable Particle (ESP) technology to make it cost and performance compatible with high multiplex assays. ESPs are optically-encoded microfabricated particles that can be manipulated using magnetic force. We will adapt our ESP-based liquid array system, which has already been successfully applied in the low multiplex space, to accommodate assays of 100,000-plex or more. ESP technology has broad applicability and should be a valuable tool in the diagnosis, prognosis, and characterization of a variety of disease states, including cancer, heart disease, arthritis and inflammatory diseases, kidney disease, liver disease, allergic responses, and infectious diseases (e.g. HIV).
ESP technology as applied to the high multiplex assay space will provide a broad platform for many different kinds of assays. The ESP platform is intrinsically versatile, and has the potential to be used in basic biomedical research, as well as high- throughput discovery and clinical diagnostics. The ability to control the particles magnetically (in a manner significantly different from magnetic beads) is a significant advantage. This technology should be useful in the diagnosis and prognosis of a variety of disease states, including cancer, heart disease, arthritis and inflammatory diseases, kidney disease, and infectious diseases (e.g. HIV).
